{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:25Z","timestamp":1777934605862,"version":"3.51.4"},"reference-count":7,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The addition of brentuximab vedotin (BV) to adriamycin, vinblastine, and dacarbazine (AVD) has become the standard-of-care approach for advanced stage Hodgkin lymphoma (HL). This case describes a rare presentation of new-onset diabetes mellitus one month after initiation of BV\u2009+\u2009AVD therapy in a patient with HL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>A 41-year-old woman with pre-diabetes and obesity was started on BV\u2009+\u2009AVD for classical HL, nodular sclerosing type. Six weeks after initiating therapy, she was admitted for abdominal pain, at which time her blood glucose was noted to be 357 mg\/dL. Her Hba1c was 8.1%. She required rapid acting insulin, and throughout admission, her glucose ranged from 132 to 263 mg\/dL. After discharge, a fasting glucose of over 250 mg\/dL deemed her ineligible to have a PET\/CT performed to assess disease status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>She was started on basal insulin, a DPP4-inhibitor, and a meglitinide analog. After initiation of therapy, her glucose levels were better controlled, and she was able to have her PET scan. Repeat Hba1c was 6.2% three months after initiation of glucose-lowering medications. She completed 6 cycles of BV\u2009+\u2009AVD therapy, with improving finger stick blood glucose (FSBG), and repeat Hba1c 1 month after completion of therapy was 5.2% on metformin monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Reports of brentuximab-induced hyperglycemia are rare in the literature, noted in just a few studies and one case report. Our case demonstrates a need to monitor blood glucose levels carefully during the initiation of BV therapy, especially in individuals with risk factors such as obesity, pre-diabetes mellitus, or diabetes mellitus.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231168951","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T19:36:11Z","timestamp":1682710571000},"page":"569-571","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["New-onset persistent hyperglycemia with initiation of brentuximab treatment"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3153-1096","authenticated-orcid":false,"given":"Joseph","family":"Quintas","sequence":"first","affiliation":[{"name":"Westchester Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelley B","family":"Mowatt","sequence":"additional","affiliation":[{"name":"Westchester Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie A","family":"Mullally","sequence":"additional","affiliation":[{"name":"Westchester Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Westchester Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003127"},{"key":"e_1_3_2_4_2","unstructured":"Seagen. Classical Hodgkin Lymphoma\u20141st line ADCETRIS\u00ae: (Brentuximab Vedotin) treatment https:\/\/www.adcetrispro.com\/previously-untreated-stage-III-IV-classical-hodgkin-lymphoma\/?gclid=3aa793db581419b5b1bff144d6261f46&gclsrc=3p.ds&&utm_source=MICROSOFT&utm_medium=cpc&utm_campaign=BS_LI_Branded_2.0&utm_content=Alone_Therapy_EX&utm_term=brentuximab&gclsrc=ds (2022 accessed 8 Aug 2022)."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-397893"},{"key":"e_1_3_2_7_2","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. [Updated 2019 May 4]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/"},{"key":"e_1_3_2_8_2","article-title":"Severe insulin resistance with diabetic ketoacidosis after brentuximab treatment","volume":"6","author":"Chiang J","year":"2020","unstructured":"Chiang J, Lai A, et al. Severe insulin resistance with diabetic ketoacidosis after brentuximab treatment. AACE Clin Case Rep 2020; 6: e98\u2013e100.","journal-title":"AACE Clin Case Rep"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231168951","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231168951","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231168951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:28:15Z","timestamp":1777688895000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231168951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/10781552231168951"],"URL":"https:\/\/doi.org\/10.1177\/10781552231168951","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]}}}